The accuracy of PRS to estimate the risk of progressive NAFLD was also evaluated in a Japanese study, in which it has been yielded that the effect of PNPLA3, GATAD2A and GCKR variations was cumulative in the increasing NASH risk, in a dose dependent manner [147]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.